FAQ

Fabrazyme

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2016
0520022016

Related topics

Related topics

1 relation

Broader (1)

agalsidase beta

Related mentions per year

Related mentions per year

2002-2018
20002005201020152020
Fabrazyme
agalsidase beta

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
CORRIGENDUM: Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)
Purpose:Fabry disease is a rare, X-linked, inherited lysosomal storage disorder that can be treated with the enzymes agalsidase… (More)
Is this relevant?
2011
2011
The Fabrazyme shortage--a call to action for metabolic physicians.
The recent shortages of enzyme replacement therapy for Fabry disease have highlighted areas of vulnerability for patients who… (More)
Is this relevant?
2010
2010
The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease.
Fabry disease is an X-linked lysosomal storage disorder caused by a deficiency in alpha-galactosidase A (alpha-Gal A) activity… (More)
Is this relevant?
2009
2009
Conditional modeling of antibody titers using a zero-inflated poisson random effects model: application to Fabrazyme®
Patients that are exposed to biotechnology-derived therapeutics often develop antibodies to the therapeutic, the magnitude of… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 2
  • figure 4
Is this relevant?
2009
2009
A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease.
Fabry disease results from a genetic deficiency of alpha-galactosidase A (alpha GAL) and the impaired catabolism of… (More)
Is this relevant?
2008
2008
Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease.
OBJECTIVE To evaluate the safety and explore the efficacy of enzyme replacement therapy with agalsidase beta (recombinant human… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.
Elsewhere, we reported the safety and efficacy results of a multicenter phase 3 trial of recombinant human alpha -galactosidase A… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2004
2004
Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease.
Fabry's disease is an X-linked lysosomal storage disease caused by a deficiency of alpha-galactosidase that results in an… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study.
BACKGROUND Enzyme replacement therapy (ERT) has been shown to enhance microvascular endothelial globotriaosylceramide clearance… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease.
Fabry disease is a lysosomal storage disease arising from deficiency of the enzyme alpha-galactosidase A. Two recombinant protein… (More)
  • table I
  • table II
  • figure 1
  • figure 2
  • table III
Is this relevant?